Comparative Pharmacology
Head-to-head clinical analysis: FENOLDOPAM MESYLATE versus HISERPIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENOLDOPAM MESYLATE versus HISERPIA.
FENOLDOPAM MESYLATE vs HISERPIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D1-like receptor agonist (D1 and D5) causing vasodilation in renal, mesenteric, coronary, and cerebral arteries; increases renal blood flow and natriuresis.
HISERPIA (risperidone) is an atypical antipsychotic that acts as a serotonin 5-HT2A and dopamine D2 receptor antagonist. It also binds to alpha1-adrenergic and histamine H1 receptors with high affinity, contributing to its therapeutic and side effect profile.
0.1 to 0.3 mcg/kg/min IV continuous infusion, titrated every 15-20 minutes by 0.05-0.1 mcg/kg/min; max dose 1.6 mcg/kg/min.
Initial: 0.25 mg orally twice daily; increase gradually to usual maintenance dose of 0.5–2 mg/day in divided doses. Maximum: 3 mg/day.
None Documented
None Documented
Terminal elimination half-life approximately 10 minutes (range 5–20 min) in healthy adults; clinically, continuous infusion is required to maintain therapeutic effect due to rapid clearance.
Terminal elimination half-life is 12-15 hours; clinically, steady-state is reached after 2-3 days of regular dosing.
Renal (80% as metabolites, 10% as unchanged drug); fecal/biliary minor (10%)
Primarily renal (60-70% as unchanged drug) and biliary/fecal (20-30% as metabolites).
Category C
Category C
Antihypertensive
Antihypertensive